TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05110963

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Uniform Standard of Care Counseling
Description: Routine HIV counseling services available to patients with protocol delivered services. Three sessions of patient education monitored for protocol adherence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Regulation Skills Counseling
Description: Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context. This is a culturally tailored adaptation of CDC disseminated Phone-Delivered Support Counseling for HIV treatment Adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Self-Regulation Skills Counseling + Stigma Management
Description: Mobile phone-delivered counseling grounded in Behavioral Self- Regulation Theory with stigma management to improve retention in HIV care and HIV viral suppression. Counseling is delivered by lay counselors in differentiated health care context with added components directly targeting stigma-related experiences and concerns.
Study: NCT06267703

Intervention type: OTHER
Intervention: Metabolomic profiling
Description: Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.

Intervention type: OTHER
Intervention: Metabolomic profiling
Description: Metabolomic profiling using serum samples was performed based on Nightingale Blood Biomarker Analysis platform; Proteomic profiling will be performed by both Scanning SWATH and OLINK® Explore 384 Oncology panel.
Study: NCT05862701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin
Description: 5% permethrin cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphur
Description: 10% Sulfur ointment
Study: NCT04072471

Intervention type: DRUG
Intervention: Zurampic®
Description: non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice

Intervention type: DRUG
Intervention: Control group: xanthine oxidase inhibitor monotherapy
Description: non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
Study: NCT05841576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMET monitoring device
Description: Cellular Oxygen METabolism (COMET) mitochondrial oxygen tension monitoring device
Study: NCT06357767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Within: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence
Description: A culturally-tailored, trauma-informed group intervention to support smoking cessation by leveraging Lakota values, mindfulness, and a storytelling approach.
Study: NCT04899206

Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.

Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.

Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.

Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.

Intervention type: DRUG
Intervention: With an Antidepressant Drug
Description: Current users of an antidepressant drug.

Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.

Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.

Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.

Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.

Intervention type: DRUG
Intervention: Without an Antidepressant Drug
Description: Non-current users of an antidepressant drug.
Study: NCT05043870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and immunosuppressives
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
Study: NCT05405842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Vagal Nerve Stimulation
Description: TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Vagal Nerve Stimulation
Description: TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transauricular Vagal Nerve Stimulation
Description: TENS 7000 is a handheld device used to deliver electrical impulses for nerve stimulation to help modulate and treat chronic pain. The manufacturer, Roscoe, has regulatory approval for the use of nerve stimulator therapy in the acute and/or prophylactic treatment of headaches, migraines, sciatica, muscle spasms, acute and chronic pain, and improve circulation. It is FDA approved in the USA for the above indications, but has not been approved for use in gastrointestinal diseases such as gastroparesis or functional dyspepsia. It has been registered as an investigational new device in various clinical trials. The purpose of this protocol is to provide vagal nerve stimulation to patients with gastroparesis, functional dyspepsia, and healthy controls as a comparison.
Study: NCT04808921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xiamen Wiz Biotech Co., Ltd. SARS-CoV-2 Antigen Rapid Test
Description: Rapid Antigen diagnostic device performance comparative to RT-PCR
Study: NCT04695158

Intervention type: DRUG
Intervention: COVID-19 group (Group I)
Description: Routine COVID-19 treatment
Study: NCT05127486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT04732663

Intervention type: OTHER
Intervention: No Intervention
Description: Cross-sectional study, no intervention.
Study: NCT06093932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songling Xuemaikang Capsules
Description: 3 capsules at a time, three times a day, duration: 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: everyday, duration: 12 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: everyday, duration: 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules at a time, three times a day, duration: 12 weeks
Study: NCT05019261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component Family Support Intervention
Description: The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.
Study: NCT05860686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monoject syringe
Description: monoject syringe is used to clean the wound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monoject syringe
Description: monoject syringe is used to clean the wound
Study: NCT05841628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532 nm laser treatment
Description: The port wine birthmark will be treated with the DermaV 532 nm laser.
Study: NCT05345990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)
Description: Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day
Study: NCT04776330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA targeted prime CAR-T cells
Description: BCMA targeted prime CAR-T cell therapy
Study: NCT05601674

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: : Conventional flow Anesthesia
Description: During the initial wash-in period 2 L/min Fresh gas flow will be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Anesthesia
Description: Fresh gas flow rate will be 0.5 L/min throughout the procedure.
Study: NCT05038293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mouthpiece-based toothbrush
Description: One-time use during study visit.
Study: NCT04695158

Intervention type: DRUG
Intervention: Type II Diabetes Mellitus and COVID-19 group (Group II)
Description: Routine Type II Diabetes Mellitus and COVID-19 treatments
Study: NCT04797169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom Health
Description: In Noom Health, participants will be encouraged to use the Noom app multiple times a day to log eating episodes, physical activity and weight. They will also have the ability to interact with coaches to receive advice and feedback specific to weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Noom Digital Health
Description: In Noom Digital Health, participants will use a simplified version to log eating episodes and weight. Both conditions will receive the same weight loss advice content.
Study: NCT05286515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Peroperative PT
Description: The intervention will consist of an in-person evaluation assessing the subject's functional level, lower and upper extremities range of motion, strength and endurance. The remaining sessions will be conducted via telehealth. The program will consist of two sessions per week up to six weeks. The program will start approximately 8 to 7 weeks before the scheduled surgery date.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical Practice PT
Description: This group will follow the protocols established by the PT facility they chose. They will finish treatment two to three weeks before the surgery date, similar to the intervention group.
Study: NCT05038293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: One-time use during study visit.
Study: NCT05195762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel 1.50%
Description: Stanford University (Stanford) is studying a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179) that has been chemically engineered for topical application to treat epidermal nevus syndromes (ENS).~Preclinical studies evaluating topical application of NFX-179 to human nevus sebaceous explants demonstrated that NFX-179 can penetrate the tissue and suppress the p-ERK biomarker.~It was also determined that NFX-179, when incubated with the tissues in medium, also suppressed ERK phosphorylation in human keratinocytic epidermal nevi. This clinical study is designed to evaluate the safety, tolerability, and clinical effect of NFX-179 Gel in Subjects with Epidermal Nevi.
Study: NCT04732663

Intervention type: OTHER
Intervention: No Intervention
Description: Cross-sectional study, no intervention.

Intervention type: OTHER
Intervention: No Intervention
Description: Cross-sectional study, no intervention.
Study: NCT06515405

Intervention type: DRUG
Intervention: Hydrocortisone
Description: Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023).

Intervention type: DRUG
Intervention: Hydrocortisone
Description: Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023).
Study: NCT05704426

Intervention type: DEVICE
Intervention: Impulse Dynamics Optimizer Device
Description: The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.

Intervention type: DEVICE
Intervention: Impulse Dynamics Optimizer Device
Description: The Impulse Dynamics Optimizer is indicated for patients with New York Heart Association (NYHA) class III congestive heart failure (CHF) with left ventricular ejection fraction (LVEF) between 25 and 45% who are not candidates for cardiac resynchronization therapy. The Optimizer device requires a minimally invasive implant by a cardiac electrophysiologist with two transvenous pacemaker wires implanted into the right ventricular septum and attached to a generator in an infraclavicular region, much like a pacemaker. The Optimizer device provides CCM through improved calcium handling and has been shown to reverse the negative remodeling of the left ventricle seen in HFrEF and improve left ventricular contractile strength.
Study: NCT06559735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CereVu Device
Description: Observational, non-invasive measurements
Study: NCT05364853

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person Testing
Description: Participants will be randomly assigned to have either in-person testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Testing
Description: Participants will be randomly assigned to have either remote testing of the DAYC-2 conducted. They will then cross over into the other testing condition approximately 3 weeks after their first assessment.
Study: NCT06558721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Lower extremity conventional rehabilitation in stroke patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Lower extremity conventional rehabilitation in stroke patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Lower extremity conventional rehabilitation in stroke patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: Mirror therapy of the lower extremity in stroke patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bicycle ergometer with functional electric stimulation
Description: Bicycle ergometer with functional electric stimulation therapy of the lower extremity in stroke patients
Study: NCT05447793

Intervention type: DEVICE
Intervention: Fitostimoline plus
Description: Formulation in gauzes and cream
Study: NCT06042140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEOX Cord 1K applied fetoscopically
Description: Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (human umbilical cord) will be used for skin closure at the discretion of the Pediatric Neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
Study: NCT05413681

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: a supra-maximal exercise test on a cycloergometer.
Description: 10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: a supra-maximal exercise test on a cycloergometer.
Description: 10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: handgrip muscle activity test.
Description: 2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: handgrip muscle activity test.
Description: 2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
Study: NCT04802837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Description: Ridinilazole 200mg dosed BID for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125mg dosed QID for 10 days.
Study: NCT05495464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given by IV (vein)
Study: NCT04827355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Upper Esophageal Sphincter (UES) Compression Device
Description: External Upper Esophageal Sphincter (UES) Compression Device fit to manufacturer guidelines.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: External Upper Esophageal Sphincter (UES) Compression Device fit to pressure known not to provide treatment.
Study: NCT06498921

Intervention type: OTHER
Intervention: Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel
Description: No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.